Steven P Govek

This inventor holds 34 USPTO granted patents and 19 published patent applications and 13 EPO patents, primarily in Receptor Modulators. Top assignees: Genentech, Inc., Kalypsys, Inc., Metacrine, Inc.. Active years: 2009-2023.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Steven P Govek. Retrieved from https://idiyas.com/inventor/steven-p-govek

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 34 (Patent Applications = 19)

% Patents Active = 70.6

EPO Patents = 13 (Patent Applications = 28)

Average Co-Inventor Count = 4.7

ph-index = 10

Forward Citations = 270(Granted Patents)

Company Filing History:

Seragon Pharmaceuticals, Inc.

patents

5. 2 out of 36

Aragon Pharmaceuticals, Inc.

patents

6. 1 out of 449

Alcon Laboratories, Inc.

Merck Sharp + Dohme Corp.

where one patent can have more than one assignee

Years Active: 2009-2023

Loading Chart...

Areas of Expertise:

Farnesoid X Receptor

Estrogen Receptor

Modulators

Inhibitors

PDE4

PPAR

Chemokine Receptors

Bicyclic Compounds

Heteroaryl

Polycyclic

Fluorinated

Azetidine

34 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11773094 - Farnesoid X receptor agonists and uses thereof (2023-10-03),

2. 11236071 - Farnesoid X receptor agonists and uses thereof (2022-02-01),

3. 11214538 - Farnesoid X receptor agonists and uses thereof (2022-01-04),

4. 11084817 - Farnesoid X receptor agonists and uses thereof (2021-08-10),

5. 10961198 - Farnesoid X receptor agonists and uses thereof (2021-03-30),

6. 10703712 - Farnesoid X receptor agonists and uses thereof (2020-07-07),

7. 10626081 - Farnesoid X receptor agonists and uses thereof (2020-04-21),

8. 10377717 - Farnesoid X receptor agonists and uses thereof (2019-08-13),

9. 10227334 - Estrogen receptor modulators and uses thereof (2019-03-12),

10. 10053451 - Heterocyclic estrogen receptor modulators and uses thereof (2018-08-21),

11. 9873684 - Estrogen receptor modulators and uses thereof (2018-01-23),

12. 9868704 - Estrogen receptor modulators and uses thereof (2018-01-16),

13. 9845291 - Estrogen receptor modulators and uses thereof (2017-12-19),

14. 9655880 - Azetidine estrogen receptor modulators and uses thereof (2017-05-23),

15. 9586952 - Polycyclic estrogen receptor modulators and uses thereof (2017-03-07),

Title: Unveiling the Innovations of Inventor Steven P Govek

Introduction: Steven P Govek, a visionary inventor hailing from San Diego, CA, has left a profound impact in the field of biotechnology with a remarkable portfolio of 34 patents. His groundbreaking work has significantly contributed to advancements in pharmaceutical compositions and medicaments, particularly in the area of farnesoid X receptor agonists.

Latest Patents: Among his notable inventions is the development of compounds that serve as farnesoid X receptor agonists. These compounds, along with the methods of their creation and utilization, have paved the way for novel approaches in treating various conditions, diseases, and disorders associated with farnesoid X receptor activity.

Career Highlights: Throughout his illustrious career, Steven P Govek has lent his expertise to esteemed companies such as Genentech, Inc. and Kalypsys, Inc. His innovative spirit and dedication to scientific excellence have been instrumental in shaping the landscape of biotechnological innovations.

Collaborations: Collaboration has been a cornerstone of Steven P Govek's success. He has worked closely with talented individuals like Nicholas D Smith and Mehmet Kahraman, fostering an environment of creativity and synergy that has propelled his inventions to new heights.

Conclusion: In conclusion, Steven P Govek stands as a beacon of innovation in the field of biotechnology, with his pioneering inventions redefining the boundaries of pharmaceutical research. His contributions have not only enriched the scientific community but also have the potential to positively impact countless lives through the treatment of challenging medical conditions.

Profile summary based on public USPTO records.